ArticleCardiovascular and interventional radiology2026
Tumor Absorbed Dose Predicts Survival and Local Tumor Control in Colorectal Liver Metastases Treated with 90Y Radioembolization.
Article in Cardiovascular and interventional radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Tumor absorbed dose and outcomes after Y-90 glass radioembolization for colorectal liver metastases: does dose escalation improve survival in real-world practice?European journal of nuclear medicine and molecular imaging · 2026Article
- Understanding Current Trends and Advances in Transarterial Radioembolization Dosimetry.Diagnostics (Basel, Switzerland) · 2025Review
- High-Dose Transarterial Radioembolization of Hepatic Metastases Using Yttrium-90 Resin Microspheres.Cancers · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundTo evaluate predictors of outcomes in colorectal liver metastases (CLM) patients undergoing 90Y radioembolization (TARE), focusing on the impact of tumor absorbed dose. MATERIALS AND
methodsPatients' characteristics and dosimetry assessments were analyzed in 231 patients undergoing 329 TARE sessions from 09/2009 to 07/2023. Response was assessed using RECIST1.1 and PERCIST criteria.
resultsPatients were predominantly male (137/231, 56.3%), had bilobar metastases (157/231, 68%) and received more than 3 lines of chemotherapy (144, 62.3%). Median age was 61 years (range 24-93). Glass and resin microspheres were used in 181/329(55%) and 148/329(45%) sessions, respectively. Weighted tumor absorbed dose covering at least 90% tumor (WTD90) ≥ 120 Gy (p = 0.043) and prior ablation (p = 0.016) were independent predictors of improved overall survival (OS) in the cohort. More than 10 CLMs (p < 0.001) and prior exposure to intra-arterial mitomycin-C (p = 0.015) were associated with decreased OS. Left colon (SHR: 1.680, 95% CI 1.136-2.484, p = 0.009) and rectal primary location (SHR: 1.586, 95% CI 1.005-2.504, p = 0.048) negatively impacted target liver progression-free survival (TLPFS), while intention to irradiate liver dose covering at least 50% tumor (ITILD50) had a positive impact (SHR: 0.955, 95% CI 0.926-0.984, p = 0.003) for the entire cohort. SIR Grade C and D complications were 1.2% and 2.7%, respectively, without correlation to dosimetry.
conclusionWTD ≥ 120 Gy was an independent predictor for improved OS after TARE for CLM regardless of microsphere type. High number of CLMs negatively impacted OS, while intention to irradiate liver dose covering at least 50% of the tumor positively impacted TLPFS.
Indexed as
Identifiers
40925975What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.